Alison L. Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alison L. Jones has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
Alan David Woolf
1 shared publicationAlan H. Hall
1 shared publicationAlberto Perez
1 shared publicationAlex T. Proudfoot
1 shared publicationAlexander B. Baer
1 shared publicationAlfred Aleguas
1 shared publication
Latest Publications
- 1 January 2007
- Published by Elsevier
CONTRIBUTORS
- Open Access
- 1 November 2003
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 96 (11) , 787-791
Hepatocellular damage from non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for the management of rheumatological disorders, and as analgesics and antipyretics. Hepatotoxicity is an uncommon, but potentially lethal complication, which usually occurs within 12 weeks of starting therapy. It can occur with all NSAIDs, but appears to be more common with diclofenac and particularly sulindac. Female patients aged >50 years, with autoimmune disease, and those on other potentially hepatotoxic drugs, appear to be particularly susceptible. Liver function test abnormalities generally settle within 4–6 weeks of stopping the causative drug. However, some patients may develop acute liver failure and successful orthotopic liver transplantation may be undertaken in such patients. Recent in vitro animal studies have shown that the mechanism of diclofenac toxicity relates both to impairment of ATP synthesis by mitochondria, and to production of active metabolites, particularly n,5-dihydroxydiclofenac, which causes direct cytotoxicity. Mitochondrial permeability transition (MPT) has also been shown to be important in diclofenac-induced liver injury, resulting in generation of reactive oxygen species, mitochondrial swelling and oxidation of NADP and protein thiols. Physicians and hepatologists must be vigilant to the hepatotoxic potential of any NSAID, as increased awareness, surveillance and reporting of these events will lead to a better understanding of the risk factors and the pathophysiology of NSAID-related hepatotoxicity.
- 1 November 2003
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 96 (11) , 787-791
Open AccessHepatocellular damage from non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for the management of rheumatological disorders, and as analgesics and antipyretics. Hepatotoxicity is an uncommon, but potentially lethal complication, which usually occurs within 12 weeks of starting therapy. It can occur with all NSAIDs, but appears to be more common with diclofenac and particularly sulindac. Female patients aged >50 years, with autoimmune disease, and those on other potentially hepatotoxic drugs, appear to be particularly susceptible. Liver function test abnormalities generally settle within 4–6 weeks of stopping the causative drug. However, some patients may develop acute liver failure and successful orthotopic liver transplantation may be undertaken in such patients. Recent in vitro animal studies have shown that the mechanism of diclofenac toxicity relates both to impairment of ATP synthesis by mitochondria, and to production of active metabolites, particularly n,5-dihydroxydiclofenac, which causes direct cytotoxicity. Mitochondrial permeability transition (MPT) has also been shown to be important in diclofenac-induced liver injury, resulting in generation of reactive oxygen species, mitochondrial swelling and oxidation of NADP and protein thiols. Physicians and hepatologists must be vigilant to the hepatotoxic potential of any NSAID, as increased awareness, surveillance and reporting of these events will lead to a better understanding of the risk factors and the pathophysiology of NSAID-related hepatotoxicity.
- Open Access
- 1 December 2002
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 95 (12) , 831-832
Paracetamol: balancing risk against benefit
- 1 December 2002
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 95 (12) , 831-832
Open AccessParacetamol: balancing risk against benefit
- 1 February 2002
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 24 (1) , 150-155
Recent Advances in the Management of Poisoning
- 1 February 2002
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 24 (1) , 150-155
Recent Advances in the Management of Poisoning
- 1 January 2002
- Published by Springer Nature in Drug Safety
- Vol. 25 (9) , 625-632
Should a Lower Treatment Line Be Used When Treating Paracetamol Poisoning in Patients with Chronic Alcoholism?
- 1 January 2002
- Published by Springer Nature in Drug Safety
- Vol. 25 (9) , 625-632
Should a Lower Treatment Line Be Used When Treating Paracetamol Poisoning in Patients with Chronic Alcoholism?
- 15 September 2001
- Vol. 323 (7313) , 633
Effects of legislation restricting pack sizes of paracetamol on self poisoning. It's too early to tell yet.
- 15 September 2001
- Vol. 323 (7313) , 633
Effects of legislation restricting pack sizes of paracetamol on self poisoning. It's too early to tell yet.
Effects of legislation restricting pack sizes of paracetamol on self poisoning
# It's too early to tell yet {#article-title-2} EDITOR—Any measure that will reduce the incidence of paracetamol poisoning is to be welcomed. Hawton et al report the impact of legislation restricting pack sizes of paracetamol and salicylate on self poisoning,1 but there are major limitations in interpretation—for example, the period studied after the legislation came into force is too short (one year) for its impact to be fully assessed. This is particularly relevant in the assessment of patients with acute liver disease as the numbers are small and there will be baseline variability.2 The data from the liver unit at King's College Hospital cross the line indicating an incidence rate ratio of 1, and the data from Leeds, Newcastle, and the Royal Free Hospital have incidences close to zero.1 The authors give data on blood paracetamol concentrations and mean number of tablets taken per paracetamol overdose, but these did not greatly change and would be the main determinant of outcome in early paracetamol poisoning.3 Certainly, prothrombin time would not be expected to be a good marker, not least because of the availability of adequate treatment with acetylcysteine. Over the same period Donogue et al examined 2020 …
Effects of legislation restricting pack sizes of paracetamol on self poisoning
# It's too early to tell yet {#article-title-2} EDITOR—Any measure that will reduce the incidence of paracetamol poisoning is to be welcomed. Hawton et al report the impact of legislation restricting pack sizes of paracetamol and salicylate on self poisoning,1 but there are major limitations in interpretation—for example, the period studied after the legislation came into force is too short (one year) for its impact to be fully assessed. This is particularly relevant in the assessment of patients with acute liver disease as the numbers are small and there will be baseline variability.2 The data from the liver unit at King's College Hospital cross the line indicating an incidence rate ratio of 1, and the data from Leeds, Newcastle, and the Royal Free Hospital have incidences close to zero.1 The authors give data on blood paracetamol concentrations and mean number of tablets taken per paracetamol overdose, but these did not greatly change and would be the main determinant of outcome in early paracetamol poisoning.3 Certainly, prothrombin time would not be expected to be a good marker, not least because of the availability of adequate treatment with acetylcysteine. Over the same period Donogue et al examined 2020 …
- 6 March 2000
- Published by Wiley in Emergency Medicine Australasia
- Vol. 12 (1) , 14-21
Recent advances in the management of late paracetamol poisoning
- 6 March 2000
- Published by Wiley in Emergency Medicine Australasia
- Vol. 12 (1) , 14-21
Recent advances in the management of late paracetamol poisoning